Over the years, Harbin Pharmaceutical Group has adhered to the corporate purpose of "making authentic drugs and being an honest enterprise". Its market share has increased rapidly, its business areas have continued to expand, and some products have entered Europe, Asia, Africa, and Central and North America. Market, annual export earnings exceed 100 million US dollars. Relying on the corporate philosophy of "integrating with integrity, winning with uniqueness, and surviving with virtue", we actively implement the brand innovation strategy and win widespread praise from all walks of life.

According to the evaluation of Beijing Famous Brand Value Asset Appraisal Co., Ltd., an authoritative domestic brand value evaluation agency, Harbin Pharmaceutical Group has become one of the most valuable pharmaceutical brands in China with a brand value of 15.19 billion yuan. Harbin Pharmaceutical Group owns four well-known Chinese trademarks, including "Harbin Pharmaceutical", "Sanjing", "Shiyitang" and "Calcium in Calcium", ranking first in the entire industry and in the three northeastern provinces. While establishing a strong brand, Harbin Pharmaceutical Group makes full use of the rich resources and conditions accumulated by the brand for the company, and invests in independent innovation with greater courage. The company invested more than 100 million yuan to build a new drug research and development system. Centering on its national-level enterprise technology center and postdoctoral workstation established in 1996, it has created technology platforms in six aspects: bioengineering, antibiotics, pharmaceutical preparations, modern traditional Chinese medicine, OTC drugs and health foods, animal vaccines and veterinary drugs. Concentrating its efforts on R&D on core technologies and core industries where it has advantages through these six platforms also marks that Harbin Pharmaceutical's new drug R&D has shifted from randomness to professionalism in the past, and has accelerated the shift from complete imitation to innovative R&D direction. .

After years of development, Harbin Pharmaceutical Group’s continuously improving independent research and development system and gradually growing scientific research team, together with its powerful brand, have formed the wings of the company’s take-off. With the help of this strong brand advantage, Harbin Pharmaceutical Group's independent research and development system has gained sufficient room for growth; and the company's brand building has also received strong driving support from the independent research and development system.